All In Biotech

Drug Trial Radar · NCT02735707

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 20,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

20,000

Planned (sponsor's estimate)

Start

Apr 11, 2016

Primary completion

Jun 2028

Study completion Feb 2029

Sponsor

Lead sponsor
UMC UtrechtAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Australian and New Zealand Intensive Care Research Centre; Medical Research Institute of New Zealand; Unity Health; Berry Consultants; Global Coalition for Adaptive Research; University of Pittsburgh Medical Center; Intensive Care National Audit & Research Centre; St. Marianna University School of Medicine; Nat Intensive Care Surveillance - MORU; National University Hospital, Singapore; Clínica Universidad de La Sabana; Universidad de la Sabana
First posted
Apr 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 28 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised patients admitted to intensive care with respiratory tract infections. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

Conditions

  • Respiratory Tract Diseases
  • Influenza (Pandemic)
  • Influenza
  • Community Acquired Pneumonia
  • Community Acquired Pneumonia (CAP)
  • Community Acquired Pneumonia, Severe
  • COVID-19
  • Respiratory Tract Infection Acute
  • Respiratory Tract Infections (RTI)
  • SARS CoV 2 Infection

Interventions

  • Ceftriaxone + MacrolideDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

  • Moxifloxacin or LevofloxacinDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

  • Piperacillin-tazobactam + MacrolideDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

  • Ceftaroline + MacrolideDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. Note: this intervention is now closed.

  • Amoxicillin-clavulanate + MacrolideDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

  • Standard course macrolideDrug

    Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5. The dosing of and route of administration is not protocolised, the following guidance is provided: * Initial IV administration of a macrolide is strongly preferred * The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted. * The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.

  • Extended course macrolideDrug

    Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first). The dosing of and route of administration is not protocolised, the following guidance is provided: * Initial IV administration of a macrolide is strongly preferred * The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted. * The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.

  • No systemic corticosteroidOther

    Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).

  • Fixed-duration HydrocortisoneDrug

    50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Note: this intervention is now closed.

  • Shock-dependent hydrocortisoneDrug

    50mg IV hydrocortisone every 6 hours while the patient is in septic shock

  • Fixed-duration higher dose HydrocortisoneDrug

    100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.

  • No antiviral agent for influenzaOther

    No antiviral agent intended to be active against influenza infection is to be administered

  • Five-days oseltamivirDrug

    Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)

  • Ten-days oseltamivirDrug

    Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)

  • No antiviral agent for COVID-19Other

    No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered

  • Lopinavir / RitonavirDrug

    Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Note: this intervention is now closed.

  • HydroxychloroquineDrug

    Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed.

  • Hydroxychloroquine + lopinavir/ritonavirDrug

    Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed.

  • IvermectinDrug

    Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day. Note: this intervention is now closed.

  • No immune modulation for COVID-19Other

    No immune modulating agent intended to be active against COVID-19 is to be administered. Note: this intervention is now closed.

  • Interferon beta-1aDrug

    IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first. Note: this intervention is now closed.

  • AnakinraDrug

    A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours. In patients with renal impairment, anakinra will be administered on alternate days. Note: this intervention is now closed.

  • TocilizumabDrug

    Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period. Note: this intervention is now closed.

  • SarilumabDrug

    Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period. Note: this intervention is now closed.

  • Local standard venous thromboprophylaxisDrug

    Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Note: this intervention is now closed.

  • Therapeutic dose anticoagulationDrug

    Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician. Note: this intervention is now closed.

  • Conventional low dose thromboprophylaxisDrug

    Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.

  • Intermediate dose thromboprophylaxisDrug

    Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.

  • Continuation of therapeutic dose anticoagulationDrug

    Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first. Note: this intervention is now closed.

  • No immunoglobulinOther

    No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.

  • Convalescent plasmaBiological

    Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.

  • Delayed administration of convalescent plasmaBiological

    Note: this intervention is now closed.

  • No vitamin COther

    No high dose intravenous vitamin C is to be administered Note: this intervention is now closed.

  • Vitamin CDrug

    Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses Note: this intervention is now closed.

  • No antiplateletOther

    No antiplatelet agent or NSAID to be administered. Note: this intervention is now closed.

  • AspirinDrug

    Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.

  • P2Y12 inhibitorDrug

    Site-selected P2Y12 inhibitor: * Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first. * Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day. * Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.

  • No simvastatinOther

    No simvastatin intended to be active against COVID-19 is to be administered Note: this intervention is now closed.

  • SimvastatinDrug

    Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation Note: this intervention is now closed.

  • EritoranDrug

    Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital Note: this intervention is now closed.

  • ApremilastDrug

    Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.

  • Clinician-preferred mechanical ventilation strategyProcedure

    Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters

  • Protocolised mechanical ventilation strategyProcedure

    Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.

  • No renin-angiotensin system inhibitorOther

    No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10. Note: this intervention is now closed.

  • Angiotensin converting enzyme inhibitorDrug

    Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.

  • Angiotensin Receptor BlockersDrug

    Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.

  • ARB + DMX-200Drug

    Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first. ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily. Note: this intervention is now closed.

  • No cysteamineOther

    No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first. Note: this intervention is now closed.

  • CysteamineDrug

    Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first. Note: this intervention is now closed.

  • Fixed-duration dexamethasoneDrug

    6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.

  • Baloxavir MarboxilDrug

    Baloxavir marboxil administered on days 1 and 4 post-randomisation.

  • Five-days oseltamivir + baloxavir marboxilDrug

    Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.

  • Ten-days oseltamivir + baloxavir marboxilDrug

    Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.

  • No endothelial modulatorOther

    No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.

  • ImatinibDrug

    Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.

  • No Immune Modulator for InfluenzaOther

    No immune modulating agent intended to be active against influenza is to be administered.

  • TocilizumabDrug

    Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.

  • BaricitinibDrug

    Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).

  • No antiviral agent for COVID-19Other

    No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered

  • Nirmatrelvir/ritonavirDrug

    Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.

  • RemdesivirDrug

    Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.

  • Nirmatrelvir/ritonavir + remdesivirDrug

    Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.

  • Amoxicillin-clavulanate + Ceftazidime + MacrolideDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

  • Meropenem + MacrolideDrug

    The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival and Recovery Trajectory up to day 90Time frame: Day 90

Locations

408 sites in 29 countries. Site status is shown where the registry gives one.

  • University of Florida

    Jacksonville, Florida · Recruiting

  • Augusta University

    Augusta, Georgia · Not yet recruiting

  • University of Illinois Health

    Chicago, Illinois · Recruiting

  • Tulane Medical Center

    New Orleans, Louisiana · Not yet recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina · Not yet recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • University of Pittsburgh Medical Centre

    Pittsburgh, Pennsylvania · Recruiting

  • Brown University - Rhode Island Hospital

    Providence, Rhode Island · Not yet recruiting

  • Canberra Hospital

    Canberra, Australian Capital Territory, Australia · Recruiting

  • Bankstown-Lidcombe Hospital

    Bankstown, New South Wales, Australia · Recruiting

  • Blacktown Hospital

    Blacktown, New South Wales, Australia · Recruiting

  • Campbelltown Hospital

    Campbelltown, New South Wales, Australia · Recruiting

  • Sutherland Hospital

    Caringbah, New South Wales, Australia · Recruiting

  • Concord Hospital

    Concord, New South Wales, Australia · Recruiting

  • Dubbo Base Hospital

    Dubbo, New South Wales, Australia · Recruiting

  • Northern Beaches Hospital

    Frenchs Forest, New South Wales, Australia · Recruiting

  • Nepean Hospital

    Kingswood, New South Wales, Australia · Recruiting

  • St. George Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Recruiting

  • John Hunter Hospital

    Newcastle, New South Wales, Australia · Recruiting

  • Orange Health Service

    Orange, New South Wales, Australia · Not yet recruiting

  • St Vincent's Hospital Sydney

    Sydney, New South Wales, Australia · Recruiting

  • Prince of Wales Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, Australia · Not yet recruiting

  • Royal North Shore Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Wollongong Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Wagga Wagga Base Hospital

    Wagga Wagga, New South Wales, Australia · Not yet recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Royal Darwin Hospital,

    Darwin, Northern Territory, Australia · Not yet recruiting

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia · Not yet recruiting

  • The Prince Charles Hospital

    Brisbane, Queensland, Australia · Recruiting

  • Mater Hospital Brisbane

    Brisbane, Queensland, Australia · Recruiting

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia · Recruiting

  • Caboolture Hospital

    Caboolture, Queensland, Australia · Recruiting

  • Queen Elizabeth II Jubilee Hospital

    Coopers Plains, Queensland, Australia · Recruiting

  • Logan Hospital

    Logan City, Queensland, Australia · Not yet recruiting

  • Redcliffe Hospital

    Redcliffe, Queensland, Australia · Not yet recruiting

Showing 40 of 408 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.